Market Fit Target BMI 27-35 consumers seeking non-systemic weight management solutions and those who prefer avoiding synthetic GLP-1 agonists, presenting a specific addressable market segment for partnerships with clinics, weight loss programs, and wellness platforms.

Regulatory edge Leverage FDA cleared status and multiple international regulatory approvals to approach hospitals, medical clinics, and insurers as a safer, non-drug device option that complements or substitutes pharmacotherapy.

Clinically validated Promote the five peer-reviewed clinical trials and Pennington Biomedical Research Center validation to sales teams as proof points for efficacy in reducing food intake and supporting weight reduction without systemic side effects.

Strategic partnerships Explore collaborations with weight management programs, obesity treatment centers, endocrinology clinics, and preventive health networks to expand adoption and co-market the device alongside lifestyle interventions.

Expansion channels Position the device for cross-border expansion leveraging existing regulatory footprints (US, Europe, Australia, Canada, Brazil) to accelerate international pilot programs with clinics, D2C wellness platforms, and telehealth services.